SpermSep in top 20

By Dylan Bushell-Embling
Friday, 20 June, 2008

NuSep's (ASX: NSP) SpermSep CS10 fertility device has been rated one of the top 20 research projects to have received Australian Research Council (ARC) funding in the last 10 years, a conference heard today.

In a speech delivered at the Graeme Clarke Outcomes Forum at Parliament House in Canberra, one of the product's developers, Professor John Aiken of the University of Newcastle, said devices like the SpermSep were particularly important in Australia, where 1 in 20 males are infertile, and a quarter of all women remain childless at the end of their reproductive lives.

SpermSep can be used to recover and process sperm for use in IVF.

In clinical trials comparing IVF using SpermSep versus Density Gradient Centrifugation (DGC), the current most common method of sperm recovery, SpermSep proved much more effective, Aiken said.

The SpermSep IVF resulted in three pregnancies from the nine women who underwent the procedure, compared to zero out of the six women in the control group who underwent IVF using DGC.

Commercial sales of SpermSep are expected to begin early next year.

Related News

Diabetes changes the structure of our hearts, study finds

Type 2 diabetes directly alters the heart's structure and energy systems, which explains why...

Beta blockers could halt triple negative breast cancer

Researchers have identified a molecular biomarker in triple negative breast cancer tumours which...

Common arthritis drug also lowers blood pressure

Scientists have known for a while that methotrexate helps with inflammation, but it may also help...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd